US Patent

US12551536 — Semaglutide in medical therapy

Method of Use · Assigned to Novo Nordisk AS · Expires 2038-10-10 · 12y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of semaglutide for weight management.

USPTO Abstract

The present invention relates to semaglutide for use in weight management.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4418`	—	Ozempic
`U-4418`	—	Ozempic

Patent Metadata

Patent number: US12551536
Jurisdiction: US
Classification: Method of Use
Expires: 2038-10-10
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.